A cost-effectiveness analysis of shortened direct-acting antiviral treatment in genotype 1 noncirrhotic treatment-naive patients with chronic hepatitis C virus by Fawsitt, C, Vickerman, P, Cooke, G, Welton, N

Changes in the prevalence of hepatitis B and C viral infections in Sindh province, Pakistan: Findings from two sero‐surveys in 2007 and 2019 by Alamneh, TS, Walker, JG, Lim, AG, Alam, E, Hamid, S, Foster, GR, Choudhry, N, Ansari, MA, Qureshi, H, Vickerman, P

Cost-effectiveness analysis of baseline testing for resistance-associated polymorphisms to optimize treatment outcome in genotype 1 noncirrhotic treatment-naïve patients with chron... by Fawsitt, C, Vickerman, P, Cooke, G, Barnes, E, Ball, J, Brainard, D, Burgess, G, Dillon, J, Foster, G, Gore, C, Guha, N, Halford, R, Whitby, K, Holmes, C, Howe, A, Hudson, E, Hutchinson, S, Irving, W, Khakoo, S, Klenerman, P, Martin, N, Massetto, B, Mbisa, T, McHutchison, J, McKeating, J, McLauchlan, J, Miners, A, Murray, A, Shaw, P, Simmonds, P, Spencer, C, Thomson, E, Zitzmann, N, Welton, N

Interferon lambda 4 impacts the genetic diversity of hepatitis C virus by Ansari, M, Aranday-Cortes, E, Ip, C, Da Silva Filipe, A, Lau, S, Bamford, C, Bonsall, D, Trebes, A, Piazza, P, Sreenu, V, Cowton, V, Stop-Hcv Consortium, Ball, J, Barnes, E, Burgess, G, Cooke, G, Dillon, J, Foster, G, Gore, C, Guha, N, Halford, R, Holmes, C, Hudson, E, Hutchinson, S, Irving, W, Khakoo, S, Klenerman, P, Martin, N, Mbisa, T, McKeating, J, McLauchlan, J, Miners, A, Murray, A, Shaw, P, Simmonds, P, Smith, S, Spencer, C, Thomson, E, Troke, P, Vickerman, P, Zitzmann, N, Hudson, E, Bowden, R, Patel, A, Foster, G, Irving, W, Agarwal, K, Thomson, E, Simmonds, P, Klenerman, P, Holmes, C, Barnes, E, Spencer, C, McLauchlan, J, Pedergnana, V